Leadership & Pay ·
Silence Therapeutics plc entered into a separation and release agreement with former executive Craig Tooman, effective…
SLNSilence Therapeutics plc
Silence Therapeutics plc entered into a separation and release agreement with former executive Craig Tooman, effective as of December 14, 2025. The agreement includes $655,000 in salary continuation, a $250,000 lump sum severance, $40,000 in legal fee reimbursement, a $283,746.03 bonus payment, $46,896.48 in healthcare premium reimbursement, and extended post-termination exercise periods for vested options. Silence Therapeutics plc is a biotechnology company focused on developing RNA interference (RNAi) technology for therapeutic use.